Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Schulz, E; Hodl, I; Forstner, P; Hatzl, S; Sareban, N; Moritz, M; Fessler, J; Dreo, B; Uhl, B; Url, C; Grisold, AJ; Khalil, M; Kleinhappl, B; Enzinger, C; Stradner, MH; Greinix, HT; Schlenke, P; Steinmetz, I.
CD19+IgD+CD27- Naïve B Cells as Predictors of Humoral Response to COVID 19 mRNA Vaccination in Immunocompromised Patients.
Front Immunol. 2021; 12:803742
Doi: 10.3389/fimmu.2021.803742
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Hodl Isabel
- Schulz Eduard
- Stradner Martin Helmut
- Co-Autor*innen der Med Uni Graz
- Dreo Barbara
- Enzinger Christian
- Fessler Johannes
- Forstner Patrick
- Greinix Hildegard
- Grisold Andrea
- Hatzl Stefan
- Khalil Michael
- Kleinhappl Barbara
- Moritz Martina
- Sareban Nazanin
- Schlenke Peter
- Steinmetz Ivo
- Uhl Barbara
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Immunocompromised patients are considered high-risk and prioritized for vaccination against COVID-19. We aimed to analyze B-cell subsets in these patients to identify potential predictors of humoral vaccination response. Patients (n=120) suffering from hematologic malignancies or other causes of immunodeficiency and healthy controls (n=79) received a full vaccination series with an mRNA vaccine. B-cell subsets were analyzed prior to vaccination. Two independent anti-SARS-CoV-2 immunoassays targeting the receptor-binding domain (RBD) or trimeric S protein (TSP) were performed three to four weeks after the second vaccination. Seroconversion occurred in 100% of healthy controls, in contrast to 67% (RBD) and 82% (TSP) of immunocompromised patients, while only 32% (RBD) and 22% (TSP) achieved antibody levels comparable to those of healthy controls. The number of circulating CD19+IgD+CD27- naïve B cells was strongly associated with antibody levels (ρ=0.761, P<0.001) and the only independent predictor for achieving antibody levels comparable to healthy controls (OR 1.07 per 10-µL increase, 95%CI 1.02-1.12, P=0.009). Receiver operating characteristic analysis identified a cut-off at ≥61 naïve B cells per µl to discriminate between patients with and without an optimal antibody response. Consequently, measuring of naïve B cells in immunocompromised hematologic patients could be useful in predicting their humoral vaccination response.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult - administration & dosage
- Aged - administration & dosage
- Antibodies, Neutralizing - immunology
- Antibodies, Viral - immunology
- B-Lymphocyte Subsets - immunology
- COVID-19 - prevention & control
- COVID-19 Vaccines - immunology
- Female - administration & dosage
- Humans - administration & dosage
- Immunocompromised Host - immunology
- Immunogenicity, Vaccine - immunology
- Male - administration & dosage
- Middle Aged - administration & dosage
- SARS-CoV-2 - administration & dosage
- Vaccines, Synthetic - immunology
- mRNA Vaccines - immunology
- Find related publications in this database (Keywords)
- mRNA vaccine
- COVID-19
- B cells
- cancer
- immunodeficiencies